Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 14/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5087438 | 0.94 | ADORA1 (0.46) | ADORA1TSHRMAPTHTTADORA3 | |
| SCHEMBL5087429 | 0.87 | ADORA1 (0.43) | ADORA1HSP90AA1MAPTHTTNPSR1 | |
| SCHEMBL5089469 | 0.86 | ADORA1 (0.49) | ADORA1TSHRSCN9A | |
| SCHEMBL5096737 | 0.86 | ADORA1 (0.47) | ADORA1SCN9AADORA3 | |
| SCHEMBL5091935 | 0.86 | ADORA1 (0.53) | ADORA1MAPTADORA3POLB | |
| SCHEMBL14288899 | 0.85 | ADORA1 (0.43) | ADORA1TSHRHTTADORA3 | |
| SCHEMBL5089431 | 0.84 | ADORA1 (0.45) | ADORA1ADORA3 | |
| SCHEMBL5089510 | 0.84 | ADORA1 (0.55) | ADORA1TSHRADORA3 | |
| SCHEMBL5090419 | 0.80 | ADORA1 (0.48) | ADORA1ADORA3 | |
| SCHEMBL5087459 | 0.80 | ADORA1 (0.43) | ADORA1MAPTADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080009531-A1 | 5-Anilino-4-Heteroarylpyrazole Derivatives Useful for the Treatment of Diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-01-10 | — | — | US | disclosed |
| US-20080009531-A1 | 5-Anilino-4-Heteroarylpyrazole Derivatives Useful for the Treatment of Diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-01-10 | — | — | US | disclosed |
| US-20080009531-A1 | 5-Anilino-4-Heteroarylpyrazole Derivatives Useful for the Treatment of Diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-01-10 | — | — | US | disclosed |
| EP-1750698-A2 | 5-ANILINO-4-HETEROARYLPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES | Bayer Pharmaceuticals Corporation (US) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005112923-A2 | 5-ANILINO-4-HETEROARYLPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009531-A1 | 5-Anilino-4-Heteroarylpyrazole Derivatives Useful for the Treatment of Diabetes | GPR119, IAPP, GLP1R | ADORA1 680/4885TSHR 1859/4885HSP90AA1 2587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.